Acadia Healthcare (NASDAQ:ACHC) Issues Q2 2026 Earnings Guidance

Acadia Healthcare (NASDAQ:ACHC) issued an update on its second quarter 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.300-0.400 for the period, compared to the consensus EPS estimate of 0.460. The company issued revenue guidance of $835.0 million-$850.0 million, compared to the consensus revenue estimate of $867.2 million.

Acadia Healthcare Stock Up 2.1%

Shares of ACHC traded up $0.53 during trading hours on Friday, reaching $26.43. The company’s stock had a trading volume of 1,385,995 shares, compared to its average volume of 3,572,178. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -2.16, a P/E/G ratio of 9.55 and a beta of 0.71. Acadia Healthcare has a 1-year low of $11.43 and a 1-year high of $28.57. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 1.27. The company has a 50 day moving average of $24.43 and a two-hundred day moving average of $19.20.

Acadia Healthcare (NASDAQ:ACHC) last issued its earnings results on Wednesday, April 29th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.09. Acadia Healthcare had a positive return on equity of 6.60% and a negative net margin of 32.84%.The company had revenue of $828.80 million for the quarter, compared to the consensus estimate of $823.51 million. During the same quarter in the prior year, the company earned $0.40 EPS. The firm’s quarterly revenue was up 7.6% on a year-over-year basis. Acadia Healthcare has set its Q2 2026 guidance at 0.300-0.400 EPS. As a group, research analysts predict that Acadia Healthcare will post 1.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. TD Cowen increased their price objective on Acadia Healthcare from $24.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Weiss Ratings restated a “sell (d)” rating on shares of Acadia Healthcare in a report on Wednesday, January 21st. Guggenheim dropped their price objective on Acadia Healthcare from $27.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, February 23rd. Leerink Partners increased their price objective on Acadia Healthcare from $14.00 to $22.00 and gave the stock a “market perform” rating in a report on Thursday, February 26th. Finally, Zacks Research upgraded Acadia Healthcare from a “strong sell” rating to a “hold” rating in a report on Thursday, March 5th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Acadia Healthcare presently has a consensus rating of “Hold” and a consensus price target of $23.04.

Key Acadia Healthcare News

Here are the key news stories impacting Acadia Healthcare this week:

• Positive Sentiment: Q1 beat — Acadia reported Q1 revenue of $828.8M (up 7.6% year-over-year) and GAAP EPS of $0.37, topping consensus estimates and showing underlying demand/patient-day growth. This explains part of the buyer interest after the print. Zacks: Q1 Earnings and Revenues Beat
• Positive Sentiment: Unusual call activity — traders bought roughly 3,427 call options (about 112% above average), signaling short-term bullish/speculative positioning that can add upward pressure on the stock in the near term.
• Neutral Sentiment: Investor materials available — management released the earnings press release, slide deck and an earnings-call presentation, useful for modeling and hearing management commentary on margins and integration. Earnings Presentation
• Negative Sentiment: Softer Q2 guidance — Acadia guided Q2 EPS to $0.30–$0.40 (consensus ~$0.46) and revenue to $835–$850M (below consensus ~$867M). The guidance miss / conservatism is the primary driver of selling pressure despite the beat. Business Wire: First Quarter Results
• Negative Sentiment: Leadership concerns — the appointment of an interim CFO raised investor questions about stability and execution risk on 2026 targets, amplifying sensitivity to lower guidance. Yahoo Finance: Interim CFO Appointment
• Negative Sentiment: Analyst/market skepticism — at least one sell-side/independent note urged selling the rally and lowered stance, and headlines highlighted that the stock “slumped” despite a healthy Q1, reinforcing negative trader sentiment. Seeking Alpha: Selling the Rally

Institutional Investors Weigh In On Acadia Healthcare

Large investors have recently added to or reduced their stakes in the stock. Mangrove Partners IM LLC acquired a new stake in Acadia Healthcare in the 4th quarter valued at approximately $363,000. Brooklyn Investment Group bought a new stake in shares of Acadia Healthcare in the fourth quarter valued at approximately $484,000. Brevan Howard Capital Management LP acquired a new stake in shares of Acadia Healthcare in the third quarter worth $392,000. Vident Advisory LLC acquired a new stake in shares of Acadia Healthcare in the third quarter worth $418,000. Finally, Corient Private Wealth LLC grew its stake in shares of Acadia Healthcare by 55.6% in the second quarter. Corient Private Wealth LLC now owns 19,056 shares of the company’s stock worth $432,000 after acquiring an additional 6,813 shares during the last quarter.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.